Trethera Corporation, a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, will attend the 2018 BIO CEO & Investor Conference on February 12-13, 2018 in New York City.
This author has yet to write their bio.Meanwhile lets just say that we are proud admin contributed a whooping 34 entries.
Entries by admin
Trethera will be presenting at the 2018 San Diego Health Impact Forum on February 7th, 2018 held at the Sanford Consortium for Regenerative Medicine in La Jolla, CA.
Los Angeles, CA / February 5, 2018 – Trethera Corporation, a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TRE-515, a novel, first-in-class inhibitor of deoxycytidine kinase for the […]
November 27, 2017 – Trethera Corporation will be attending the American Society of Hematology (ASH) Annual Meeting in Atlanta from December 9-12, 2017. Trethera is preparing for initiation of a Phase 1 clinical trial in myelodysplastic syndrome (MDS) for its small molecule, deoxycytidine kinase inhibitor, TRE-515.
September 7, 2017 – Trethera, a biotechnology company developing innovative small molecule inhibitors of cancer nucleotide metabolism, will be attending the BioPharma America conference in Boston, MA, September 26-27, 2017.
September 7, 2017 – Trethera, a biotechnology company developing innovative small molecule inhibitors of cancer nucleotide metabolism, will be attending RESI Boston 2017 on September 26, 2017.
September 7, 2017 – Trethera will be attending the Society of Hematologic Oncology’s Annual Meeting, September 13-15, 2017, in Houston, Texas. For more information on Trethera’s attendance, please contact email@example.com
Abstract Leukemia cells rely on two nucleotide biosynthetic pathways, de novo and salvage, to produce dNTPs for DNA replication. Here, using metabolomic, proteomic, and phosphoproteomic approaches, we show that inhibition of the replication stress sensing kinase ataxia telangiectasia and Rad3-related protein (ATR) reduces the output of both de novo and salvage pathways by regulating the […]
Santa Monica, CA, 26 January 2017 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Sachs Associates 10th Annual European Life Sciences CEO Forum & Exhibition being held on 6th-7th March, 2017 at the Hilton Zurich Airport Hotel, Switzerland. […]
25 January 2017 SCRIP Emerging Company Profile: University spinout, Trethera – which recently signed a licensing deal to develop Nanotherapeutics Inc.’s ribonucleotide reductase inhibitor Triapine – believes it is the first company to target cancer nucleotide metabolism through a combination approach. Read Article